Achieve Life Sciences

A new CEO with prior hands‑on experience scaling commercial respiratory assets joined in April 2026, complemented by senior hires who executed a recent best‑in‑class respiratory launch later acquired by a large pharma.

The regulatory and manufacturing reset has been communicated clearly, and the company is aligning its CMC and field infrastructure to the updated timeline. Execution from here will validate the team’s quality.